H.U. Group Holdings, Inc. (hereinafter, the Company) hereby announces the consolidated earnings forecast for the fiscal year ending March 31, 2021, which had not been determined at the time of our announcement of "Consolidated Financial Results for the Fiscal Year Ended March 31, 2020" publicized on May 13, 2020.
1. Earnings forecasts
Consolidated Earnings Forecasts for the six months ending September 30, 2020 (from April 1, 2020 to September 30, 2020)
Operating
Ordinary
Profit attributable
Earnings per
Net sales
to owners of
profit
profit
share
(¥ millions)
parent
(¥ millions)
(¥ millions)
(¥)
(¥ millions)
Previous forecast (A)
－
－
－
－
－
Revised forecast (B)
97,500
7,000
undetermined
undetermined
undetermined
Change (B-A)
－
－
－
－
Change (%)
－
－
－
－
(Ref.) Six months ended
September 30, 2019
93,480
5,758
4,526
2,544
44.67
(Consolidated)
Consolidated Earnings Forecasts for the fiscal year ending March 31, 2021 (from April 1, 2020 to March 31, 2021)
Operating
Ordinary
Profit (Loss)
Earnings per
Net sales
attributable to
profit
profit
share
(¥ millions)
owners of parent
(¥ millions)
(¥ millions)
(¥)
(¥ millions)
Previous forecast (A)
－
－
－
－
－
Revised forecast (B)
200,000
14,000
undetermined
undetermined
undetermined
to 220,000
to 18,500
Change (B-A)
－
－
－
－
Change (%)
－
－
－
－
(Ref.) Fiscal year ended
March 31, 2020
188,712
9,939
6,468
(516)
(9.06)
(Consolidated)
- 1 -
(3) Reasons for the announcement
The consolidated financial forecasts for the fiscal year ending March 31, 2021 had not been determined due to difficulties in making reasonable estimates of the COVID-19 pandemic impact. However, as it has become possible for the Company to estimate the forecasts to a certain degree based on the latest available information, the Company hereby announces the above forecasts.
(4) Reasons for the forecasts
Test volume in CLT business, which significantly decreased in April and May due to the COVID-19
pandemic, has recovered to the similar level as the previous year since the month of June. Also, increased number of COVID-19 related tests and sales of the antigen tests (both high-sensitive reagents "Lumipulse SARS-CoV-2 Ag" and rapid test kit "ESPLINE SARS-CoV-2") began to contribute to our earnings, recovering our consolidated business performance. Considering these factors, the Company forecasts consolidated net sales of 97.5 billion yen and consolidated operating profit of 7.0 billion yen for the first six months of the fiscal year ending March 31, 2021.
In and after the third quarter, the Company is not expecting as large decline of test volume in CLT business as it experienced in the months of April to May. However, the outlook of demands for COVID-19 related tests and the aforementioned antigen tests remains unclear to elaborate precise earnings forecasts for the full year. Therefore, the Company has decided to disclose full-year consolidated net sales and consolidated operating profit in a range.
As for the forecasts of ordinary profit and profit attributable to owners of parent, the Company has decided to maintain them as undetermined. This is due to the remaining uncertainties from the impact of COVID-19 pandemic on business performances of the companies accounted for using the equity method in the United States and China. Accordingly, the Company will also maintain the dividend forecast undermined.
The earnings forecasts above are based on information available to management at the time of preparation of this document. Actual performance may vary from forecasts.
- 2 -
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Miraca Holdings Inc. published this content on 18 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2020 05:04:02 UTC
H.U. Group Holdings Inc, formerly Miraca Holdings Inc is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and sterilization related business. The Company operates in four business segments. The Outsourced Clinical Testing segment accepts special tests from medical institutions. The Clinical Laboratory Medicine segment manufactures and sells clinical laboratory medicines and sells them to medical institutions and contract clinical laboratory companies. The Sterilization segment mainly entrusts the sterilization of medical equipment used for medical treatment in hospitals of large-scale hospitals and the related operations. The New Development & Others segment is involved in the homecare & welfare equipment business, self-medication & health insurance business, food & environment & cosmetics inspection business.
H.U. GROUP HOLDINGS, INC. 
